Cerus Corporation Q1 2026 Financial Results and Guidance Increase

Cerus Corporation reported strong first quarter 2026 financial results with total revenue of $59.9 million, representing a 23% year-over-year increase. Product revenue grew 24% to $53.7 million, driven by strength in the global platelet franchise and increased U.S. INTERCEPT Fibrinogen Complex (IFC) sales. The company raised its full-year 2026 product revenue guidance to $227-231 million, reflecting 10-12% growth from 2025. Net loss improved significantly to $1.6 million ($0.01 per share) compared to a $7.7 million loss ($0.04 per share) in Q1 2025. Non-GAAP adjusted EBITDA was $4.0 million, up from $0.2 million. The company also announced leadership changes with Vivek Jayaraman appointed as President and CEO effective July 1, 2026, while William "Obi" Greenman will become Executive Chairman.